Trade

with

Transcept Pharmaceuticals Inc
(NASDAQ: TSPT)
AdChoices
1.75
-0.05
-2.78%
After Hours :
-
-
-

Open

1.80

Previous Close

1.80

Volume (Avg)

141.41k (68.24k)

Day's Range

1.55-1.80

52Wk Range

1.55-3.90

Market Cap.

34.49M

Dividend Rate ( Yield )

-

Beta

0.86

Shares Outstanding

19.16M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 1.75M

    • Net Income

    • -27.45M

    • Market Cap.

    • 34.49M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,046.55

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.86

    • Forward P/E

    • -

    • Price/Sales

    • 21.10

    • Price/Book Value

    • 0.80

    • Price/Cash flow

    • -4.42

      • EBITDA

      • -27.28M

      • Return on Capital %

      • -26.05

      • Return on Equity %

      • -26.88

      • Return on Assets %

      • -26.05

      • Book Value/Share

      • 2.19

      • Shares Outstanding

      • 19.16M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -24.70

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -50.80

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -336.13

            • 82.75

            • Pre-Tax Margin

            • -1,046.55

            • 39.38

            • Net Profit Margin

            • -1,046.55

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 19.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -438.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 17.79

              • 2.92

              • Quick Ratio

              • 17.42

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.06

              • 2.21

              • Book Value/Share

              • 2.19

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.44

                • 217.39

                • P/E Ratio 5-Year High

                • -16.99

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.07

                • 124.82

                • Price/Sales Ratio

                • 25.58

                • 9.52

                • Price/Book Value

                • 0.97

                • 8.61

                • Price/Cash Flow Ratio

                • -4.42

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -26.88

                        (-19.10)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -26.05

                        (-17.30)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -26.88

                        (-19.00)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.02

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -27.37M
                      Operating Margin
                      -1,566.74
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -4.42
                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Value

                      Transcept Pharmaceuticals, Inc. was incorporated in Delaware in February 2001. It is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs...more in the field of neuroscience. Intermezzo or zolpidem tartrate sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. The Company competes with Ambien and Ambien CR marketed by sanofi-aventis, Lunesta marketed by Sunovion Pharmaceuticals Inc., Rozerem marketed by Takeda Pharmaceuticals Company Limited, Sonata marketed by King Pharmac...moreeuticals, Inc. and generic forms of this product, Silenor, a product developed by Somaxon Pharmaceuticals, Inc., and a number of other pharmaceutical agents. The Company is subject to the government regulations of the state and country.lessless

                      Key People

                      Glenn A. Oclassen

                      CEO/Chairman of the Board/Director/President

                      Ms. Leone Patterson

                      CFO/Chief Accounting Officer/Vice President

                      Matthew M. Loar

                      Director

                      Jake R. Nunn

                      Director

                      G. Kirk Raab

                      Director

                      • Transcept Pharmaceuticals Inc

                      • 1003 W. Cutting Blvd

                      • Point Richmond, CA 94804

                      • USA.Map

                      • Phone: +1 510 215-3500

                      • Fax: +1 510 215-3535

                      • transcept.com

                      Incorporated

                      2001

                      Employees

                      8